Posts by Claude Dagenais
Glycovax Pharma commercializes an outstanding CRM197
The new performant carrier protein developed under license
from the National Research Council Canada.
Glycovax Pharma Joins Forces with NRC and Université de Montréal to Combat Pseudomonas aeruginosa
Glycovax Pharma partners with the National Research Council of Canada (NRC) and Université de Montréal to advance vaccine research targeting the drug-resistant bacterium Pseudomonas aeruginosa, aiming to address a major global health threat.
Read MoreGlycovax Pharma launches a highly performant SLA Adjuvant
Developed through a licence from the
National Research Council Canada
Glycovax Pharma develops a vaccine to fight Pa-related infections
Glycovax Pharma, NRC, and Université de Montréal are collaborating to develop a vaccine against Pseudomonas aeruginosa, a bacterium causing severe infections in cystic fibrosis patients.
Read More